Signal Transduct Target Ther:人脐带间充质干细胞治疗COVID-19患者的安全性如何?

2021-06-12 MedSci原创 MedSci原创

对于COVID-19,目前还没有有效的药物治疗方法。针对导致幸存者肺部组织损伤、死亡或长期功能障碍的潜在异常免疫反应的宿主导向疗法需要行进一步的临床评估。近日,研究人员进行了一项平行分配的对照、非随机

对于COVID-19,目前还没有有效的药物治疗方法。针对导致幸存者肺部组织损伤、死亡或长期功能障碍的潜在异常免疫反应的宿主导向疗法需要行进一步的临床评估。近日,研究人员进行了一项平行分配的对照、非随机的1期临床试验,评估了人脐带间充质干细胞(UC-MSCs)输注治疗中重度COVID-19肺部疾病患者的安全性,研究结果已发表于Signal Transduct Target Ther。

研究招募了18名住院的COVID-19患者(每组n = 9)。治疗组在第0、3和6天接受三个周期的UC-MSCs静脉输注(每次输注3×107个细胞)。两组患者都接受标准的COVID-治疗方案。分析了不良事件、临床症状持续时间、实验室参数、住院时间、连续胸部计算机断层扫描(CT)图像、PaO2/FiO2比率、细胞因子的动态变化以及IgG和IgM抗SARS-CoV-2抗体。

 

研究过程中并没有观察到严重的UC-MSCs输注相关的不良事件。两名接受UC-MSCs的患者出现一过性面部潮红和发烧,一名患者在输注UC-MSCs12小时后出现一过性缺氧。治疗组有一名患者需要机械通气,而对照组则有四名。最终所有患者都康复出院。

综上,该研究数据显示,对中重度COVID-19患者静脉输注UC-MSCs是安全的,而且耐受性良好。需要进行有长期随访的2/3期随机、对照、双盲试验,以评估UC-MSCs的治疗用途,以减少死亡和改善严重COVID-19患者的长期治疗效果。

 

原始出处:

 

Fanping Meng, Ruonan Xu, et al., Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. Signal Transduct Target Ther. 2020 Aug 27;5(1):172. doi: 10.1038/s41392-020-00286-5.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1795518, encodeId=3eae1e955188d, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sun Jul 18 05:58:56 CST 2021, time=2021-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036219, encodeId=ba8e2036219e7, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Wed Jul 21 13:58:56 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657510, encodeId=4235165e510ff, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri May 13 01:58:56 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815564, encodeId=2ef91815564d1, content=<a href='/topic/show?id=ae359e231d4' target=_blank style='color:#2F92EE;'>#间充质干细#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97231, encryptionId=ae359e231d4, topicName=间充质干细)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Mon Aug 30 06:58:56 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794033, encodeId=f0b61e94033e2, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Thu May 12 03:58:56 CST 2022, time=2022-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974235, encodeId=a27a9e42358b, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a41c5478152, createdName=ms6000000002490719, createdTime=Thu Jun 17 00:06:20 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025568, encodeId=80c3102556831, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Tue Jun 15 23:58:56 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297533, encodeId=0df4129e533ac, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Mon Jun 14 14:58:56 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542431, encodeId=72451542431c3, content=<a href='/topic/show?id=82c0846654a' target=_blank style='color:#2F92EE;'>#脐带#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84665, encryptionId=82c0846654a, topicName=脐带)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06713409761, createdName=1249859em42(暂无昵称), createdTime=Mon Jun 14 14:58:56 CST 2021, time=2021-06-14, status=1, ipAttribution=)]
    2021-07-18 闆锋旦
  2. [GetPortalCommentsPageByObjectIdResponse(id=1795518, encodeId=3eae1e955188d, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sun Jul 18 05:58:56 CST 2021, time=2021-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036219, encodeId=ba8e2036219e7, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Wed Jul 21 13:58:56 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657510, encodeId=4235165e510ff, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri May 13 01:58:56 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815564, encodeId=2ef91815564d1, content=<a href='/topic/show?id=ae359e231d4' target=_blank style='color:#2F92EE;'>#间充质干细#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97231, encryptionId=ae359e231d4, topicName=间充质干细)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Mon Aug 30 06:58:56 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794033, encodeId=f0b61e94033e2, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Thu May 12 03:58:56 CST 2022, time=2022-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974235, encodeId=a27a9e42358b, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a41c5478152, createdName=ms6000000002490719, createdTime=Thu Jun 17 00:06:20 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025568, encodeId=80c3102556831, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Tue Jun 15 23:58:56 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297533, encodeId=0df4129e533ac, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Mon Jun 14 14:58:56 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542431, encodeId=72451542431c3, content=<a href='/topic/show?id=82c0846654a' target=_blank style='color:#2F92EE;'>#脐带#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84665, encryptionId=82c0846654a, topicName=脐带)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06713409761, createdName=1249859em42(暂无昵称), createdTime=Mon Jun 14 14:58:56 CST 2021, time=2021-06-14, status=1, ipAttribution=)]
    2021-07-21 楚秀娟
  3. [GetPortalCommentsPageByObjectIdResponse(id=1795518, encodeId=3eae1e955188d, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sun Jul 18 05:58:56 CST 2021, time=2021-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036219, encodeId=ba8e2036219e7, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Wed Jul 21 13:58:56 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657510, encodeId=4235165e510ff, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri May 13 01:58:56 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815564, encodeId=2ef91815564d1, content=<a href='/topic/show?id=ae359e231d4' target=_blank style='color:#2F92EE;'>#间充质干细#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97231, encryptionId=ae359e231d4, topicName=间充质干细)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Mon Aug 30 06:58:56 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794033, encodeId=f0b61e94033e2, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Thu May 12 03:58:56 CST 2022, time=2022-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974235, encodeId=a27a9e42358b, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a41c5478152, createdName=ms6000000002490719, createdTime=Thu Jun 17 00:06:20 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025568, encodeId=80c3102556831, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Tue Jun 15 23:58:56 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297533, encodeId=0df4129e533ac, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Mon Jun 14 14:58:56 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542431, encodeId=72451542431c3, content=<a href='/topic/show?id=82c0846654a' target=_blank style='color:#2F92EE;'>#脐带#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84665, encryptionId=82c0846654a, topicName=脐带)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06713409761, createdName=1249859em42(暂无昵称), createdTime=Mon Jun 14 14:58:56 CST 2021, time=2021-06-14, status=1, ipAttribution=)]
    2022-05-13 bsmagic9140
  4. [GetPortalCommentsPageByObjectIdResponse(id=1795518, encodeId=3eae1e955188d, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sun Jul 18 05:58:56 CST 2021, time=2021-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036219, encodeId=ba8e2036219e7, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Wed Jul 21 13:58:56 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657510, encodeId=4235165e510ff, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri May 13 01:58:56 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815564, encodeId=2ef91815564d1, content=<a href='/topic/show?id=ae359e231d4' target=_blank style='color:#2F92EE;'>#间充质干细#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97231, encryptionId=ae359e231d4, topicName=间充质干细)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Mon Aug 30 06:58:56 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794033, encodeId=f0b61e94033e2, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Thu May 12 03:58:56 CST 2022, time=2022-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974235, encodeId=a27a9e42358b, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a41c5478152, createdName=ms6000000002490719, createdTime=Thu Jun 17 00:06:20 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025568, encodeId=80c3102556831, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Tue Jun 15 23:58:56 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297533, encodeId=0df4129e533ac, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Mon Jun 14 14:58:56 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542431, encodeId=72451542431c3, content=<a href='/topic/show?id=82c0846654a' target=_blank style='color:#2F92EE;'>#脐带#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84665, encryptionId=82c0846654a, topicName=脐带)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06713409761, createdName=1249859em42(暂无昵称), createdTime=Mon Jun 14 14:58:56 CST 2021, time=2021-06-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1795518, encodeId=3eae1e955188d, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sun Jul 18 05:58:56 CST 2021, time=2021-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036219, encodeId=ba8e2036219e7, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Wed Jul 21 13:58:56 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657510, encodeId=4235165e510ff, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri May 13 01:58:56 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815564, encodeId=2ef91815564d1, content=<a href='/topic/show?id=ae359e231d4' target=_blank style='color:#2F92EE;'>#间充质干细#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97231, encryptionId=ae359e231d4, topicName=间充质干细)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Mon Aug 30 06:58:56 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794033, encodeId=f0b61e94033e2, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Thu May 12 03:58:56 CST 2022, time=2022-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974235, encodeId=a27a9e42358b, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a41c5478152, createdName=ms6000000002490719, createdTime=Thu Jun 17 00:06:20 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025568, encodeId=80c3102556831, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Tue Jun 15 23:58:56 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297533, encodeId=0df4129e533ac, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Mon Jun 14 14:58:56 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542431, encodeId=72451542431c3, content=<a href='/topic/show?id=82c0846654a' target=_blank style='color:#2F92EE;'>#脐带#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84665, encryptionId=82c0846654a, topicName=脐带)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06713409761, createdName=1249859em42(暂无昵称), createdTime=Mon Jun 14 14:58:56 CST 2021, time=2021-06-14, status=1, ipAttribution=)]
    2022-05-12 yaanren
  6. [GetPortalCommentsPageByObjectIdResponse(id=1795518, encodeId=3eae1e955188d, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sun Jul 18 05:58:56 CST 2021, time=2021-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036219, encodeId=ba8e2036219e7, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Wed Jul 21 13:58:56 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657510, encodeId=4235165e510ff, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri May 13 01:58:56 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815564, encodeId=2ef91815564d1, content=<a href='/topic/show?id=ae359e231d4' target=_blank style='color:#2F92EE;'>#间充质干细#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97231, encryptionId=ae359e231d4, topicName=间充质干细)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Mon Aug 30 06:58:56 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794033, encodeId=f0b61e94033e2, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Thu May 12 03:58:56 CST 2022, time=2022-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974235, encodeId=a27a9e42358b, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a41c5478152, createdName=ms6000000002490719, createdTime=Thu Jun 17 00:06:20 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025568, encodeId=80c3102556831, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Tue Jun 15 23:58:56 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297533, encodeId=0df4129e533ac, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Mon Jun 14 14:58:56 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542431, encodeId=72451542431c3, content=<a href='/topic/show?id=82c0846654a' target=_blank style='color:#2F92EE;'>#脐带#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84665, encryptionId=82c0846654a, topicName=脐带)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06713409761, createdName=1249859em42(暂无昵称), createdTime=Mon Jun 14 14:58:56 CST 2021, time=2021-06-14, status=1, ipAttribution=)]
    2021-06-17 ms6000000002490719

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1795518, encodeId=3eae1e955188d, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sun Jul 18 05:58:56 CST 2021, time=2021-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036219, encodeId=ba8e2036219e7, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Wed Jul 21 13:58:56 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657510, encodeId=4235165e510ff, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri May 13 01:58:56 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815564, encodeId=2ef91815564d1, content=<a href='/topic/show?id=ae359e231d4' target=_blank style='color:#2F92EE;'>#间充质干细#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97231, encryptionId=ae359e231d4, topicName=间充质干细)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Mon Aug 30 06:58:56 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794033, encodeId=f0b61e94033e2, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Thu May 12 03:58:56 CST 2022, time=2022-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974235, encodeId=a27a9e42358b, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a41c5478152, createdName=ms6000000002490719, createdTime=Thu Jun 17 00:06:20 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025568, encodeId=80c3102556831, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Tue Jun 15 23:58:56 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297533, encodeId=0df4129e533ac, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Mon Jun 14 14:58:56 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542431, encodeId=72451542431c3, content=<a href='/topic/show?id=82c0846654a' target=_blank style='color:#2F92EE;'>#脐带#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84665, encryptionId=82c0846654a, topicName=脐带)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06713409761, createdName=1249859em42(暂无昵称), createdTime=Mon Jun 14 14:58:56 CST 2021, time=2021-06-14, status=1, ipAttribution=)]
    2021-06-15 独孤立克

    干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1795518, encodeId=3eae1e955188d, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sun Jul 18 05:58:56 CST 2021, time=2021-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036219, encodeId=ba8e2036219e7, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Wed Jul 21 13:58:56 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657510, encodeId=4235165e510ff, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri May 13 01:58:56 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815564, encodeId=2ef91815564d1, content=<a href='/topic/show?id=ae359e231d4' target=_blank style='color:#2F92EE;'>#间充质干细#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97231, encryptionId=ae359e231d4, topicName=间充质干细)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Mon Aug 30 06:58:56 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794033, encodeId=f0b61e94033e2, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Thu May 12 03:58:56 CST 2022, time=2022-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974235, encodeId=a27a9e42358b, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a41c5478152, createdName=ms6000000002490719, createdTime=Thu Jun 17 00:06:20 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025568, encodeId=80c3102556831, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Tue Jun 15 23:58:56 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297533, encodeId=0df4129e533ac, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Mon Jun 14 14:58:56 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542431, encodeId=72451542431c3, content=<a href='/topic/show?id=82c0846654a' target=_blank style='color:#2F92EE;'>#脐带#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84665, encryptionId=82c0846654a, topicName=脐带)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06713409761, createdName=1249859em42(暂无昵称), createdTime=Mon Jun 14 14:58:56 CST 2021, time=2021-06-14, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1795518, encodeId=3eae1e955188d, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sun Jul 18 05:58:56 CST 2021, time=2021-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036219, encodeId=ba8e2036219e7, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Wed Jul 21 13:58:56 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657510, encodeId=4235165e510ff, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri May 13 01:58:56 CST 2022, time=2022-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1815564, encodeId=2ef91815564d1, content=<a href='/topic/show?id=ae359e231d4' target=_blank style='color:#2F92EE;'>#间充质干细#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97231, encryptionId=ae359e231d4, topicName=间充质干细)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Mon Aug 30 06:58:56 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794033, encodeId=f0b61e94033e2, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Thu May 12 03:58:56 CST 2022, time=2022-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974235, encodeId=a27a9e42358b, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a41c5478152, createdName=ms6000000002490719, createdTime=Thu Jun 17 00:06:20 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025568, encodeId=80c3102556831, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Tue Jun 15 23:58:56 CST 2021, time=2021-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297533, encodeId=0df4129e533ac, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Mon Jun 14 14:58:56 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542431, encodeId=72451542431c3, content=<a href='/topic/show?id=82c0846654a' target=_blank style='color:#2F92EE;'>#脐带#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84665, encryptionId=82c0846654a, topicName=脐带)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06713409761, createdName=1249859em42(暂无昵称), createdTime=Mon Jun 14 14:58:56 CST 2021, time=2021-06-14, status=1, ipAttribution=)]

相关资讯

JAMA Psychiatry:精神分裂症频谱障碍是COVID-19患者死亡的危险因素

精神分裂症频谱障碍可能是COVID-19患者死亡的危险因素

Lancet子刊:超6900万人队列研究再次证实,BMI升高与严重COVID-19不良结局相关

即使BMI在23kg /m2以上的小幅增加,也是感染SARS-CoV-2后不良结局的危险因素。

Transl Psychiatry:学生心理健康问题并不能通过病毒控制自发解决

在学校开学初期,学生的心理和行为问题出人意料地增加,学生心理健康脆弱性并不能通过病毒控制自发解决。

梅斯心血管疾病进展(004期)

编者按:梅斯医学将定期进行汇总,帮助大家概览心血管领域最新进展。下面是呈现给大家的最新一期的心血管进展。enjoy~

阿司匹林并不能提高COVID-19住院病人的生存率

据英国康复试验报道,阿司匹林不能提高covid-19住院患者的生存率。

口罩相关痤疮(maskne)和其它面部皮肤病

并不是所有与个人防护设备有关的面部皮肤病都是“maskne”。除了对皮肤状况进行标准的医疗治疗外,维护皮肤屏障和定期“摘口罩”是管理的重要方面